Human disease and drug pharmacology, complex as real life

Current Medicinal Chemistry

Volumn 20, Issue 13, 2013, Pages 1623-1634

  Viayna, E ^a   Sola, I ^a   Di Pietro, O ^a   Munoz Torrero D ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Multitarget drugs; Multitarget therapies; Network pharmacology; Polypharmacology; Protein interaction networks

Indexed keywords

BRIVARACETAM; CLORAZIL; CLOZAPINE; DASATINIB; DOPAMINE RECEPTOR; ERLOTINIB; ETIRACETAM; G PROTEIN COUPLED RECEPTOR; GEFITINIB; HALOPERIDOL; IMATINIB; LAPATINIB; MUSCARINIC RECEPTOR; OLANZAPINE; SEROTONIN RECEPTOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG REPOSITIONING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME STRUCTURE; HEREDITY; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOLOGICAL SCIENCE; PROTEIN EXPRESSION; PROTEIN INTERACTION; PSYCHOPHARMACOLOGY;

ANIMALS; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; PROTEIN INTERACTION MAPS;

EID: 84877947846     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320130002     Document Type: Article

References (140)

1. Lee, J.A.; Uhlik, M.T.; Moxham, C.M.; Tomandl, D.; Sall, D.J. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J. Med. Chem., 2012, 55, 4527-4538.
2. Macarron, R.; Banks, M.N.; Bojanic, D.; Burns, D.J.; Cirovic, D.A.; Garyantes, T.; Green, D.V.S.; Hertzberg, R.P.; Janzen, W.P.; Paslay, J.W.; Schopfer, U.; Sittampalam, G.S. Impact of highthroughput screening in biomedical research. Nat. Rev. Drug Discov., 2011, 10, 188-195.
3. Huang, S. Rational drug discovery: What can we learn from regulatory networks? Drug Discov. Today, 2002, 7, S163-169.
4. Janga, S.C.; Tzakos, A. Structure and organization of drug-target networks: Insights from genomic approaches for drug discovery. Mol. BioSyst., 2009, 5, 1536-1548.
5. Hopkins, A.L. Network pharmacology. Nat. Biotechnol., 2007, 25, 1110-1111.
6. Kaufmann, S.H. Paul Ehrlich: Founder of chemotherapy. Nat. Rev. Drug Discov., 2008, 7, 373.
7. Costantino, L.; Barlocco, D. Designed multiple ligands: Basic research vs clinical outcomes. Curr. Med. Chem., 2012, 19, 3353-3387.
8. Betz, U.A.K. How many genomics targets can a portfolio afford? Drug Discov. Today, 2005, 10, 1057-1063.
9. Almog, D. Drug industry in "depression". Med. Sci. Monit., 2005, 11, SR1-SR4.
10. Overington, J.P.; Al-Lazikani, B.; Hopkins, A. How many drug targets are there? Nat. Rev. Drug. Discov., 2006, 5, 993-996.
11. Yildirim, M.A.; Goh, K.I.; Cusick, M.E.; Barabási, A.L.; Vidal, M. Drug-target network. Nat. Biotechnol., 2007, 25, 1119-1126.
12. Booth, B.; Zemmel, R. Prospects for productivity. Nat. Rev. Drug Discov., 2004, 3, 451-456.
13. Swinney, D.C.; Anthony, J. How were new medicines discovered? Nat. Rev. Drug Discov., 2011, 10, 507-519.
14. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 2004, 3, 711-716.
15. Cohen, F.J. Macro trends in pharmaceutical innovation. Nat. Rev. Drug Discov., 2005, 4, 78-84.
16. Sams-Dodd, F. Target-based drug discovery: Is something wrong? Drug Discov. Today, 2005, 10, 139-147.
17. Margineanu, D.G. Systems biology impact on antiepileptic drug discovery. Epilepsy Res., 2012, 98, 104-115.
18. van der Greef, J.; McBurney, R.N. Rescuing drug discovery: In vivo systems pathology and systems pharmacology. Nat. Rev. Drug Discov., 2005, 4, 961-967.
19. Hopkins, A.L. Network pharmacology: The next paradigm in drug discovery. Nat. Chem. Biol., 2008, 4, 682-690.
20. Pujol, A.; Mosca, R.; Farrés, J.; Aloy, P. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol. Sci., 2010, 31, 115-123.
21. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem., 2005, 48, 6523-6543.
22. Lansbury, P.T., Jr. Back to the future: The "old-fashioned" way to new medications for neurodegeneration. Nat. Med., 2004, 10, S51-S57.
23. Barabási, A.L.; Oltvai, Z.N. Network biology: Understanding the cell's functional organization. Nat. Rev. Genet., 2004, 5, 101-113.
24. Vidal, M. Interactome modeling. FEBS Lett., 2005, 579, 1834-1838.
25. Stein, A.; Mosca, R.; Aloy, P. Three-dimensional modeling of protein interactions and complexes is going 'omics. Curr. Opin. Struct. Biol., 2011, 21, 200-208.
26. Ellis, R.J.; Minton, A.P. Join the crowd. Nature, 2003, 425, 27-28.
27. Ellis, R.J. Macromolecular crowding: Obvious but underappreciated. Trends Biochem. Sci., 2001, 26, 597-604.
28. Hall, D.; Minton, A.P. Macromolecular crowding: Qualitative and semiquantitative successes, quantitative challenges. Biochim. Biophys. Acta, 2003, 1649, 127-139.
29. Csermely, P.; Agoston, V.; Pongor, S. The efficiency of multitarget drugs: The network approach might help drug design. Trends Pharmacol. Sci., 2005, 26, 178-182.
30. Chen, Y.; Zhu, J.; Lum, P.Y.; Yang, X.; Pinto, S.; MacNeil, D.J.; Zhang, C.; Lamb, J.; Edwards, S.; Sieberts, S.K.; Leonardson, A.; Castellini, L.W.; Wang, S.; Champy, M.F.; Zhang, B.; Emilsson, V.; Doss, S.; Ghazalpour, A.; Horvath, S.; Drake, T.A.; Lusis, A.J.; Schadt, E.E. Variations in DNA elucidate molecular networks that cause disease. Nature, 2008, 452, 429-435.
31. Kitano, H. Systems biology: A brief overview. Science, 2002, 295, 1662-1664.
32. Zanzoni, A.; Soler-López, M.; Aloy, P. A network medicine approach to human disease. FEBS Lett., 2009, 583, 1759-1765.
33. Kitano, H. Biological robustness. Nat. Rev. Genet., 2004, 5, 826-837.
34. Kitano, H. A robustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov., 2007, 6, 202-210.
35. Woodcock, J.; Griffin, J.P.; Behrman, R.E. Development of novel combination therapies. N. Engl. J. Med., 2011, 17, 364, 985-987.
36. Albert, R.; Jeong, H.; Barabasi, A.L. Error and attack tolerance of complex networks. Nature, 2000, 406, 378-382.
37. Kitano, H. Towards a theory of biological robustness. Mol. Syst. Biol., 2007, 3, 137.
38. Cho, C.R.; Labow, M.; Reinhardt, M.; van Oostrum, J.; Peitsch, M.C. The application of systems biology to drug discovery. Curr. Opin. Chem. Biol., 2006, 10, 294-302.
39. Mencher, S.K.; Wang, L.G. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin. Pharmacol., 2005, 5, 3.
40. Roth, B.L.; Scheffler, D.J.; Kroeze, W.K. Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov., 2004, 3, 353-359.
41. Bianchi, M.T.; Pathmanathan, J.; Cash, S.S. From ion channels to complex networks: Magic bullet versus magic shotgun approaches to anticonvulsant pharmacotherapy. Med. Hypotheses, 2009, 72, 297-305.
42. Jia, J.; Zhu, F.; Ma, X.; Cao, Z.W.; Li, Y.X.; Chen, Y.Z. Mechanisms of drug combinations: Interaction and network perspectives. Nat. Rev. Drug Discov., 2009, 8, 111-128.
43. Erickson, R.P. From "magic bullet" to "specially engineered shotgun loads": The new genetics and the need for individualized pharmacotherapy. Bioessays, 1998, 20, 683-685.
44. Stephenson, V.C.; Heyding, R.A.; Weaver, D.F. "The promiscuous drug concept" with applications to Alzheimer's disease. FEBS Lett., 2005, 579, 1338-1342.
45. Bianchi, M.T.; Botzolakis, E.J. Targeting ligand-gated ion channels in neurology and psychiatry: Is pharmacological promiscuity an obstacle or an opportunity? BMC Pharmacol., 2010, 10, 3.
46. Fields, S.; Song, O. A novel genetic system to detect protein-protein interactions. Nature, 1989, 340, 245-246.
47. Eyckerman, S.; Lemmens, I.; Catteeuw, D.; Verhee, A.; Vandekerckhove, J.; Lievens, S.; Tavernier, J. Reverse MAPPIT: Screening for protein-protein interaction modifiers in mammalian cells. Nat. Methods, 2005, 2, 427-433.
48. Paumi, C.M.; Menendez, J.; Arnoldo, A.; Engels, K.; Iyer, K.R.; Thaminy, S.; Georgiev, O.; Barral, Y.; Michaelis, S.; Stagljar, I. Mapping protein-protein interactions for the yeast ABC transporter Ycf1p by integrated split ubiquitin membrane yeast two-hybrid analysis. Mol. Cell, 2007, 26, 15-25.
49. Jansen, R.; Yu, H.; Greenbaum, D.; Kluger, Y.; Krogan, N.J.; Chung, S.; Emili, A.; Snyder, M.; Greenblatt, J.F.; Gerstein, M. A Bayesian networks approach for predicting protein-protein interactions from genomic data. Science, 2003, 302, 449-453.
50. Lu, L.J.; Xia, Y.; Yu, H.; Rives, A.; Lu, H.; Schubert, F.; Gerstein, M.B. Protein interaction prediction by integrating genomic features and protein interaction network analysis. In: Data Analysis and Visualization in Genomics and Proteomics; Azuaje, F.; Dopazo, J. Eds.; Wiley: 2005, pp. 61-81.
51. Shen, J.; Zhang, J.; Luo, X.; Zhu, W.; Yu, K.; Chen, K.; Li, Y.; Jiang, H. Predicting protein-protein interactions based only on sequences information. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 4337-4341.
52. Jensen, L.J.; Kuhn, M.; Stark, M.; Chaffron, S.; Creevy, C.; Muller, J.; Doerks, T.; Julien, P.; Roth, A.; Simonovic, M.; Bork, P.; von Mering, C. STRING 8-A global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res., 2009, 37, D412-D416.
53. Zhang, M.; Su, S.; Bhatnagar, R.K.; Hassett, D.J.; Lu, L.J. Prediction and analysis of the protein interactome in Pseudomonas aeruginosa to enable network-based drug target selection. PLOS ONE, 2012, 7, e41202.
54. Schadt, E.E.; Friend, S.H.; Shaywitz, D.A. A network view of disease and compound screening. Nat. Rev. Drug. Discov., 2009, 8, 286-295.
55. Uetz, P.; Giot, L.; Cagney, G.; Mansfield, T.A.; Judson, R.S.; Knight, J.R.; Lockshon, D.; Narayan, V.; Srinivasan, M.; Pochart, P.; Qureshi-Emili, A.; Li, Y.; Godwin, B.; Conover, D.; Kalbfleisch, T.; Vijayadamodar, G.; Yang, M.; Johnston, M.; Fields, S.; Rothberg, J.M. A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature, 2000, 403, 623-627.
56. Ito, T.; Chiba, T.; Ozawa, R.; Yoshida, M.; Hattori, M.; Sakaki, Y. A comprehensive two-hybrid analysis to explore the yeast protein interactome. Proc. Natl. Acad. Sci. U.S.A., 2001, 98, 4569-4574.
57. Gavin, A.C.; Aloy, P.; Grandi, P.; Krause, R.; Boesche, M.; Marzioch, M.; Rau, C.; Jensen, L.J.; Bastuck, S.; Dümpelfeld, B.; Edelmann, A.; Heurtier, M.A.; Hoffman, V.; Hoefert, C.; Klein, K.; Hudak, M.; Michon, A.M.; Schelder, M.; Schirle, M.; Remor, M.; Rudi, T.; Hooper, S.; Bauer, A.; Bouwmeester, T.; Casari, G .; Drewes, G.; Neubauer, G.; Rick, J.M.; Kuster, B.; Bork, P.; Russell, R.B.; Superti-Furga, G. Proteome survey reveals modularity of the yeast call machinery. Nature, 2006, 440, 631-636.
58. Krogan, N.J.; Cagney, G.; Yu, H.; Zhong, G.; Guo, X.; Ignatchenko, A.; Li, J.; Pu, S.; Datta, N.; Tikuisis, A.P.; Punna, T.; Peregrín-Alvarez, J.M.; Shales, M.; Zhang, X.; Davey, M.; Robinson, M.D.; Paccanaro, A.; Bray, J.E.; Sheung, A.; Beattie, B.; Richards, D.P.; Canadien, V.; Lalev, A.; Mena, F.; Wong, P.; Starostine, A.; Canete, M.M.; Vlasblom, J.J.; Wu, S.; Orsi, C.; Collins, S.R.; Chandran, S.; Haw, R.; Rilstone, J.J.; Gandi, K.; Thompson, N.J.; Musso, G.; St Onge, P.; Ghanny, S.; Lam, M.H.Y.; Butland, G.; Altaf-Ul, A.M.; Kanaya, S.; Shilatifard, A.; O'Shea, E.; Weissman, J.S.; Ingles, C.J.; Hughes, T.R.; Parkinson, J.; Gerstein, M.; Wodak, S.J.; Emili, A.; Greenblatt, J.F. Global landscape of protein complexes in the yeast Saccharomyces cerevisiae. Nature, 2006, 440, 637-643.
59. Giot, L.; Bader, J.S.; Brouwer, C.; Chaudhuri, A.; Kuang, B.; Li, Y.; Hao, Y.L.; Ooi, C.E.; Godwin, B.; Vitols, E.; Vijayadamodar, G.; Pochart, P.; Machineni, H.; Welsh, M.; Kong, Y.; Zerhusen, B.; Malcolm, R.; Varrone, Z.; Collis, A.; Minto, M.; Burgess, S.; McDaniel, L.; Stimpson, E.; Spriggs, F.; Williams, J.; Neurath, K.; Ioime, N.; Agee, M.; Voss, E.; Furtak, K.; Renzulli, R.; Aanensen, N.; Carrolla, S.; Bickelhaupt, E.; Lazovatsky, Y.; DaSilva, A.; Zhong, J.; Stanyon, C.A.; Finley Jr., R.L.; White, K.P.; Braverman, M.; Jarvie, T.; Gold, S.; Leach, M.; Knight, J.; Shimkets, R.A.; McKenna, M.P.; Chant, J.; Rothberg, J.M. A protein interaction map of Drosophila melanogaster. Science, 2003, 302, 1727-1736.
60. Li, S.; Armstrong, C.M.; Bertin, N.; Ge, H.; Milstein, S.; Boxem.; M.; Vidalain, P.O.; Han, J.D.; Chesneau, A.; Hao, T.; Goldberg, D.S.; Li, N.; Martinez, M.; Rual, J.F.; Lamesch, P.; Xu, L.; Tewari, M.; Wong, S.L.; Zhang, L.V.; Berriz, G.F.; Jacotot, L.; Vaglio, P.; Reboul, J.; Hirozane-Kishikawa, T.; Li, Q.; Gabel, H.W.; Elewa, A.; Baumgartner, B.; Rose, D.J.; Yu, H.; Bosak, S.; Sequerra, R.; Fraser, A.; Mango, S.E.; Saxton, W.M.; Strome, S.; Van der Heuvel, S.; Piano, F.; Vandenhaute, J.; Sardet, C.; Gerstein, M.; Doucette-Stamm, L.; Gunsalus, K.C.; Harper, J.W.; Cusick, M.E.; Roth, F.P.; Hill, D.E.; Vidal, M. A map of the interactome network of the metazoan C. elegans. Science, 2004, 303, 540-543.
61. Rual, J.F.; Venkatesan, K.; Hao, T.; Hirozane-Kishikawa, T.; Dricot, A.; Li, N.; Berriz, G.F.; Gibbons, F.D.; Dreze, M.; Ayivi-Guedehoussou, N.; Klitgord, N.; Simon, C.; Boxem, M.; Milstein, S.; Rosenberg, J.; Goldberg, D.S.; Zhang, L.V.; Wong, S.L.; Franklin, G.; Li, S.; Albala, J.S.; Lim, J.; Fraughton, C.; Llamosas, E.; Cevik, S.; Bex, C.; Lamesch, P.; Sikorski, R.S.; Vandenhaute, J.; Zoghbi, H.Y.; Smolyar, A.; Bosak, S.; Sequerra, R.; Doucette-Stamm, L.; Cusick, M.E.; Hill, D.E.; Roth, F.P.; Vidal, M. Towards a proteome-scale map of the human protein-protein interaction network. Nature, 2005, 437, 1173-1178.
62. Stelzl, U.; Worm, U.; Lalowski, M.; Haenig, C.; Brembeck, F.H.; Goehler, H.; Stroedicke, M.; Zenkner, M.; Schoenherr, A.; Koeppen, S.; Timm, J.; Mintzlaff, S.; Abraham, C.; Bock, N.; Kietzmann, S.; Goedde, A.; Toksöz, E.; Droege, A.; Krobitsch, S.; Korn, B.; Birchmeier, W.; Lehrach, H.; Wanker, E.E. A human proteinprotein interaction network: A resource for annotating the proteome. Cell, 2005, 122, 957-968.
63. Ewing, R.M.; Chu, P.; Elisma, F.; Li, H.; Taylor, P.; Climie, S.; McBroom-Cerajewski, L.; Robinson, M.D.; O'Connor, L.; Li, M.; Taylor, R.; Dharsee, M.; Ho, Y.; Heilbut, A.; Moore, L.; Zhang, S.; Ornatsky, O.; Bukhman, Y.V.; Ethier, M.; Sheng, Y.; Vasilescu, J.; Abu-Farha, M.; Lambert, J.P.; Duewel, H.S.; Stewart, I.I.; Kuehl, B.; Hogue, K.; Colwill, K.; Gladwish, K.; Muskat, B.; Kinach, R.; Adams, S.L.; Moran, M.F.; Morin, G.B.; Topaloglou, T.; Figeys, D. Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol. Syst. Biol., 2007, 3, 89.
64. Soler-López, M.; Zanzoni, A.; Lluís, R.; Stelzl, U.; Aloy, P. Interactome mapping suggests new mechanistic details underlying Alzheimer's disease. Genome Res., 2011, 21, 364-376.
65. Charbonnier, S.; Gallego, O.; Gavin, A.C. The social network of a cell: Recent advances in interactome mapping. Biotechnol. Annu. Rev., 2008, 14, 1-28.
66. Soler-López, M.; Badiola, N.; Zanzoni, A.; Aloy, P. Towards Alzheimer's root cause: ECSIT as an integrating hub between oxidative stress, inflammation and mitochondrial dysfunction. Bioessays, 2012, 34, 532-541.
67. Shirasaki, D.I.; Greiner, E.R.; Al-Ramahi, I.; Gray, M.; Boontheung, P.; Geschwind, D.H.; Botas, J.; Coppola, G.; Horvath, S.; Loo, J.A.; Yang, W. Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron, 2012, 75, 41-57.
68. Stumpf, M.P.H.; Thorne, T.; de Silva, E.; Stewart, R.; An, H.J.; Lappe, M.; Wiuf, C. Estimating the size of the human interactome. Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 6959-6964.
69. Goh, K.-I.; Cusick, M.E.; Valle, D.; Childs, B.; Vidal, M.; Barabasi, A.-L. The human disease network. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 8685-8690.
70. Nacher, J.C.; Schwartz, J.-M. A global view of drug-therapy interactions. BMC Pharmacol., 2008, 8, 5.
71. Yu, H.; Chen, J.; Xu, X.; Li, Y.; Zhao, H.; Fang, Y.; Li, X.; Zhou, W.; Wang, W.; Wang, Y. A systematic prediction of multiple drugtarget interactions from chemical, genomic, and pharmacological data. PLoS One, 2012, 7, 1-14.
72. Yang, L.; Chen, J.; Shi, L.; Hudock, M.P.; Wang, K.; He, L. Identifying unexpected therapeutic targets via chemical-protein interactome. PLoS One, 2010, 5, 1-11.
73. Mestres, J.; Gregori-Puigjané, E.; Valverde, S.; Solé, R.V. The topology of drug-target interaction networks: Implicit dependence on drug properties and target families. J. Mol. BioSyst., 2009, 5, 1051-1057.
74. Mestres, J.; Gregori-Puigjané, E.; Valverde, S.; Solé, R.V. Data completeness-The Achilles heel of drug-target networks. Nat. Biotechnol., 2008, 26, 983-984.
75. Hopkins, A.L. Predicting promiscuity. Nature, 2009, 462, 167-168.
76. Keith, C.T.; Borisy, A.A.; Stockwel, B.R. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov., 2005, 4, 71-78.
77. Frantz, S. Drug discovery: Playing dirty. Nature, 2005, 437, 942-943.
78. Hampton, T. "Promiscuous" anticancer drugs that hit multiple targets may thwart resistance. JAMA, 2004, 292, 419-422.
79. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov., 2002, 1, 493-502.
80. Giles, F.J.; O'Dwyer, M.; Swords, R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia, 2009, 23, 1698-1707.
81. Drews, J. Case histories, magic bullets and the state of drug discovery. Nat. Rev. Drug. Discov., 2006, 5, 635-640.
82. Karaman, M.W.; Herrgard, S.; Treiber, D.K.; Gallant, P.; Atteridge, C.E.; Campbell, B.T.; Chan, K.W.; Ciceri, P.; Davis, M.I; Edeen, P.T.; Faraoni, R.; Floyd, M.; Hunt, J.P.; Lockhart, D.J.; Milanov, Z.V.; Morrison, M.J.; Pallares, G.; Patel, H.K.; Pritchard, S.; Wodicka, L.M.; Zarrinkar, P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol., 2008, 26, 127-132.
83. Knight, Z.A.; Lin, H.; Shokat, K.M. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer, 2010, 10, 130-137.
84. Faivre, S.; Demetri, G.; Sargent, W.; Raymond, E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov., 2007, 6, 734-745.
85. Lieberman, J.A.; Stroup, T.S.; McEvoy, J.P.; Swartz, M.S.; Rosenheck, R.A.; Perkins, D.O.; Keefe, R.S.E.; Davis, S.M.; Davis, C.E.; Lebowitz, B.D.; Severe, J.; Hsiao, J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med., 2005, 353, 1209-1223.
86. Yadav, P.N.; Abbas, A.I.; Farrell, M.S.; Setola, V.; Sciaky, N.; Huang, X.-P.; Kroeze, W.K.; Crawford, L.K.; Piel, D.A.; Keiser, M.J.; Irwin, J.J.; Schoichet, B.K.; Deneris, E.S.; Gingrich, J.; Beck, S.G.; Roth, B.L. The presynaptic component of the serotonergic system is required for clozapine's efficacy. Neuropsychopharmacol., 2011, 36, 638-651.
87. Keiser, M.J.; Roth, B.L.; Armbruster, B.N.; Ernsberger, P.; Irwin, J.J.; Shoichet, B.K. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol., 2007, 25, 197-206.
88. Keiser, M.J.; Setola, V.; Irwin, J.J.; Laggner, C.; Abbas, A.I.; Hufeisen, S.J.; Jensen, N.H.; Kuijer, M.B.; Matos, R.C.; Tran, T.B.; Whaley, R.; Glennon, R.A.; Hert, J.; Thomas, K.L.H.; Edwards, D.D.; Shoichet, B.K.; Roth, B.L. Predicting new molecular targets for known drugs. Nature, 2009, 462, 175-181.
89. Lynch, B.A.; Lambeng, N.; Nocka, K.; Kensel-Hammes, P.; Bajjalieh, S.M.; Matagne, A.; Fuks, B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetirazetam. Proc. Natl. Acad. Sci. U.S.A., 2004, 101, 9861-9866.
90. Brodie, M.J.; Kwan, P. Staged approach to epilepsy management. Neurology, 2002, 58, S2-S8.
91. Rogawski, M.A. Brivaracetam: A rational drug discovery success story. Br. J. Pharmacol., 2008, 154, 1555-1557.
92. Rogawski, M.A.; Löscher, W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci., 2004, 5, 553-564.
93. Bianchi, M.T. Promiscuous modification of ion channels by antipsychotic and anti-dementia medications. Med. Hypotheses, 2010, 74, 297-300.
94. Wertheimer, A.I. The economics of polypharmacology: Fixed dose combinations and drug cocktails. Curr. Med. Chem., 2013, 20, in press.
95. Bolognesi, M.L. Polypharmacology in a single drug: Multitarget drugs. Curr. Med. Chem., 2013, 20, in press.
96. Liu, X.; Zhu, F.; Ma, X.H.; Shi, Z.; Yang, S.Y.; Wei, Y.Q.; Chen, Y.Z. Predicting targeted polypharmacology for drug repositioning and multi-target drug discovery. Curr. Med. Chem., 2013, 20, in press.
97. Geldenhuys, W.J.; Van der Schyf, C.J. Rationally designed multitargeted agents against neurodegenerative diseases. Curr. Med. Chem., 2013, 20, in press.
98. Chen, X.; Decker, M. Multi-target compounds acting in the central nervous system designed from natural products. Curr. Med. Chem., 2013, 20, in press.
99. Russo, P.; Frustaci, A.; Fini, M.; Cesario, A. Multitarget drugs of plants origin acting on Alzheimer's disease. Curr. Med. Chem., 2013, 20, in press.
100. Chen, Z.; Han, L.; Xu, M.; Xu, Y.; Qian, X. Rationally designed multitarget anticancer agents. Curr. Med. Chem., 2013, 20, in press.
101. Njogu, P.M.; Chibale, K. Recent developments in rationally designed multitarget antiprotozoan agents. Curr. Med. Chem., 2013, 20, in press.
102. Zhan, P.; Liu, X. Rationally designed multitarget anti-HIV agents. Curr. Med. Chem., 2013, 20, in press.
103. Bisi, A.; Gobbi, S.; Belluti, F.; Rampa, A. Design of multifunctional compounds for cardiovascular disease: From natural scaffolds to "classical" multitarget approach. Curr. Med. Chem., 2013, 20, in press.
104. Hwang, S.H.; Wecksler, A.T.; Wagner, K.; Hammock, B.D. Rationally designed multitarget agents against inflammation and pain. Curr. Med. Chem., 2013, 20, in press.
105. O'Connor, K.A.; Roth, B.L. Finding new tricks for old drugs: An efficient route for public-sector drug discovery. Nat. Rev. Drug Discov., 2005, 4, 1005-1014.
106. Ashburn, T.T.; Thor, K.B. Drug repositioning: Identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov., 2004, 3, 673-683.
107. Oprea, T.I.; Bauman, J.E.; Bologa, C.G.; Buranda, T.; Chigaev, A.; Edwards, B.S.; Jarvik, J.W.; Gresham, H.D.; Haynes, M.K.; Hjelle, B.; Hromas, R.; Hudson, L.; Mackenzie, D.A.; Muller, C.Y.; Reed, J.C.; Simons, P.C.; Smagley, Y.; Strouse, J.; Surviladze, Z.; Thompson, T.; Ursu, O.; Waller, A.; Wandinger-Ness, A.; Winter, S.S.; Wu, Y.; Young, S.M.; Larson, R.S.; William, C.; Sklar, L.A. Drug repurposing from an academic perspective. Drug Discov. Today, 2011, 8, 61-69.
108. Doan, T.L.; Pollastri, M.; Walters, M.A.; Georg, G.I. The future of drug repositioning: Old drugs, new opportunities. Annu. Rep. Med. Chem., 2011, 46, 385-401.
109. Aubé, J. Drug repurposing and the medicinal chemist. ACS Med. Chem. Lett., 2012, 3, 442-444.
110. Blum, L.C.; Reymond, J.L. 970 Million druglike small molecules for virtual screening in the chemical universe database GDB-13. J. Am. Chem. Soc., 2009, 131, 8732-8733.
111. Ekins, S.; Mestres, J.; Testa, B. In silico pharmacology for drug discovery: Methods for virtual ligand screening and profiling Br. J. Pharmacol., 2007, 152, 9-20.
112. Nonell-Canals, A.; Mestres, J. In silico target profiling of one billion molecules. Mol. Inf., 2011, 30, 405-409.
113. Yang, L; Agarwal, P. Systematic drug repositioning based on clinical side-effects. PLoS ONE, 2011, 6, e28025.
114. Durrant, J.D.; Amaro, R.E.; Xie, L.; Urbaniak, M.D.; Ferguson, M.A.J.; Haapalainen, A.; Chen, Z.; Di Guilmi, A.M.; Wunder, F.; Bourne, P.E.; McCammon, J.A. A multidimensional strategy to detect polyphamacological targets in the absence of structural and sequence homology. PLoS Comp. Biol., 2010, 6, e1000648.
115. Duran-Frigola, M.; Aloy, P. Recycling side-effects into clinical makers for drug repositioning. Genome Med., 2012, 4, 3.
116. Boguski, K.S.; Mandl, K.D.; Sukhatme, V.P. Drug discovery. Repurposing with a difference. Science, 2009, 324, 1394-1395.
117. Wermuth, C.G. Selective optimization of side activities: Another way for drug discovery. J. Med. Chem., 2004, 47, 1303-1314.
118. Wermuth, C.G. The "SOSA" approach: An alternative to highthroughput screening. Med. Chem. Res., 2001, 10, 431-439.
119. Wermuth, C.G. Multitargeted drugs: The end of the "one-targetone- disease" philosophy? Drug Discov. Today, 2004, 9, 826-827.
120. Zimmermann, G.R.; Lehár, J.; Keith, C.T. Multi-target therapeutics: When the whole is greater than the sum of the parts. Drug Discov. Today, 2007, 12, 34-42.
121. Cole, G.M.; Frautschy, S.A. Commentary on "cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery." Pleiotropic approaches to Alzheimer's and other diseases of aging. Alzheimer's Dementia, 2006, 2, 284-286.
122. Podolsky, S.H.; Greene, J.A. Combination drugs-hype, harm and hope. N. Engl. J. Med., 2011, 365, 488-491.
123. Volpe, M.; Chin, D.; Paneni, F. The challenge of polypharmacy in cardiovascular medicine. Fundament. Clin. Pharmacol., 2010, 24, 9-17.
124. Zhou, H.; Tong, Z.; McLeod, J.F. "Cocktail" approaches and strategies in drug development: Valuable tool or flawed science? J. Clin. Pharmacol., 2004, 44, 120-134.
125. Radhakrishnan, M.L.; Tidor, B. Optimal drug cocktail design: Methods for targeting molecular ensembles and insights from theoretical model systems. J. Chem. Inf. Model., 2008, 48, 1055-1073.
126. Borisy, A.A.; Elliott, P.J.; Hurst, N.W.; Lee, M.S.; Lehár, J.; Price, E.R.; Serbedzija, G.; Zimmermann, G.R.; Foley, M.A.; Stockwell, B.R.; Keith, C.T. Systematic discovery of multipotent therapeutics. Proc. Natl. Sci. U.S.A., 2003, 100, 7977-7982.
127. Araujo, R.P.; Petricoin, E.F.; Liotta, L.A. A mathematical model of combination therapy using the EGFR signalling network. Biosystems, 2005, 80, 57-69.
128. Lehár, J.; Krueger, A.S.; Avery, W.; Heilbut, A.M.; Johansen, L.M.; Price, E.R.; Rickles, R.J.; Short III, G.F.; Staunton, J.E.; Jin, X.; Lee, M.S.; Zimmermann, G.R.; Borisy, A.A. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol., 2009, 27, 659-666.
129. Bangalore, S.; Kamalakkannan, G.; Parkar, S.; Messerli, F.H. Fixed-dose combinations improve medication compliance: A metaanalysis. Am. J. Med., 2007, 120, 713-719.
130. Cavalli, A.; Bolognesi, M.L. Minarini, A, ; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem., 2008, 51, 347-372.
131. García-Donaire, J.A.; Ruilope, L.M. "Multiple action fixed combination. Present or future?". Fundament. Clin. Pharmacol., 2010, 24, 37-42.
132. Guidance for industry-codevelopment of two or more unmarketed investigational drugs for use in combination, Rockville, M.D. Food and Drug Administration. 2010 (draft). (http://www.fda.gov/downloads/Drugs/Guidance/ UMC236669.pdf) .
133. Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M.B.H. Ladostigil: A novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr. Drug Targets, 2012, 13, 483-494.
134. Morphy, R.; Rankovic, Z. The physicochemical challenges of designing multiple ligands. J. Med. Chem., 2006, 49, 4961-4970.
135. Morphy, R.; Rankovic, Z. Designing multiple-ligands-medicinal chemistry strategies and challenges. Curr. Pharm. Des., 2009, 15, 587-600.
136. Morphy, R.; Rankovic, Z. Fragments, network biology and designing multiple ligands. Drug Discov. Today, 2007, 12, 156-160.
137. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today, 2004, 9, 641-651.
138. Hann, M.M.; Leach, A.R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci., 2001, 41, 856-864.
139. Hopkins, A.L.; Mason, J.S.; Overington, J.P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol., 2006, 16, 127-136.
140. Huggins, D.J.; Sherman, W.; Tidor, B. Rational approaches to improving selectivity in drug design. J. Med. Chem., 2012, 55, 1424-1444.